Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Paliperidone extended-release tablets, used to treat schizophrenia and schizoaffective disorder. The approval covers strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg. The market size for these tablets is estimated at USD 48 million for the year ending June 2024.
